Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Kristen Hege, MD
Celgene Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California San Francisco
San Francisco, California, United States
- University of Florida College of Med
Gainesville, Florida, United States
- Moffitt Cancer Center
Tampa, Florida, United States
- Indiana University Cancer Center
Indianapolis, Indiana, United States
- Henry Ford Hospital
Detroit, Michigan, United States
- Greenville Hospital System
Greenville, South Carolina, United States
- University of Utah Huntsman Cancer Institute
Salt Lake City, Utah, United States
- Seattle Cancer Care Alliance
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 16 Jan 2015
- Primary completion
- 21 Dec 2016
- Completion
- 21 Dec 2016
- Last update posted
- 20 Mar 2017
- Registered enrollment
- 12
- Registry id
- NCT02323906
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.